Immunome, Inc. (IMNM)

NASDAQ: IMNM · IEX Real-Time Price · USD
3.83
-0.17 (-4.25%)
Dec 7, 2022 11:39 AM EST - Market open
-4.25%
Market Cap 48.52M
Revenue (ttm) n/a
Net Income (ttm) -37.58M
Shares Out 12.13M
EPS (ttm) -2.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,330
Open 3.81
Previous Close 4
Day's Range 3.37 - 3.83
52-Week Range 2.09 - 17.76
Beta 0.43
Analysts Buy
Price Target 8.67 (+126.4%)
Earnings Date Nov 21, 2022

About IMNM

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. [Read more]

Industry Biotechnology
IPO Date Oct 2, 2020
Employees 39
Stock Exchange NASDAQ
Ticker Symbol IMNM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for IMNM stock is "Buy." The 12-month stock price forecast is 8.67, which is an increase of 126.37% from the latest price.

Price Target
$8.67
(126.37% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immunome Reports Third Quarter 2022 Financial Results

EXTON, Pa.--( BUSINESS WIRE )--Immunome, Inc. (Nasdaq: IMNM), a clinical stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody th...

3 weeks ago - Business Wire

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer's ...

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody ther...

1 month ago - Business Wire

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients wit...

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

3 months ago - Business Wire

Immunome Reports Second Quarter 2022 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

4 months ago - Business Wire

Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US,...

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

5 months ago - Business Wire

Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

5 months ago - Business Wire

Immunome to Present at the Jefferies Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

6 months ago - Business Wire

Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

6 months ago - Business Wire

Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data

Immunome Inc (NASDAQ: IMNM) shares are trading higher after it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the omicron variant (BA.1) when tested in vi...

6 months ago - Benzinga

Why Immunome Shares Are Rising

Immunome Inc (NASDAQ: IMNM) shares are trading higher by 19.44% at $3.39 after the company published data demonstrating its COVID-19 antibody cocktail IMM-BCP-01 cleared the omicron variant of SARS-CoV-...

6 months ago - Benzinga

Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Mode...

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

6 months ago - Business Wire

Immunome Reports First Quarter 2022 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

6 months ago - Business Wire

Immunome Reports Fourth Quarter and Full Year 2021 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

8 months ago - Business Wire

Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain

Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.

8 months ago - Zacks Investment Research

FDA Lifts Clinical Hold on Immunome's IMM-BCP-01 IND Application for the Treatment of COVID-19

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

8 months ago - Business Wire

FDA Lifts Clinical Hold on Immunome's COVID-19 Candidate IND

The FDA has lifted the clinical hold on Immunome Inc's (NASDAQ: IMNM) Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) to treat COVID-19.  Immunome previously announced ...

8 months ago - Benzinga

Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus

Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-antibody cocktail against live versions of the COVID-19 omicron variant. Get the Inside Access Tr...

9 months ago - Benzinga

Immunome's Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

9 months ago - Business Wire

FDA Issues Clinical Hold On Immunome's COVID-19 Antibody Program

Immunome Inc (NASDAQ: IMNM) has received an FDA clinical hold letter in response to its recently submitted IND requesting further information related to the preparation and administration of IMM-BCP-01 ...

10 months ago - Benzinga

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

10 months ago - Business Wire

Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

1 year ago - Business Wire

Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, annou...

1 year ago - Business Wire

Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of CO...

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, annou...

1 year ago - Business Wire

Immunome Reports Third Quarter 2021 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2021 Financial Results

1 year ago - Business Wire

Immunome to Present at the Stifel Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Stifel Healthcare Conference

1 year ago - Business Wire